Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P S Esper

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Journal of Nursing Education|February 1, 1995
Facing transition--nurse clinician to nurse educatorP S Esper
Seminars in Urologic Oncology|February 1, 1997
Supportive care in the patient with hormone refractory prostate cancerP S Esper, K J Pienta
Annals of Internal Medicine|May 15, 1993
Risk factors for prostate cancerK J Pienta, P S Esper
American Journal of Clinical Oncology|October 1, 1996
A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostateK J Pienta, B G Redman, P S Esper, et al.
American Journal of Clinical Oncology|February 1, 1997
Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostateK J Pienta, P S Esper, F Zwas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostateK J Pienta, B Redman, M Hussain, et al.
Urology|September 25, 1997
A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancerK J Pienta, B G Redman, R Bandekar, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Journal of Nursing Education|February 1, 1995
Facing transition--nurse clinician to nurse educatorP S Esper
Seminars in Urologic Oncology|February 1, 1997
Supportive care in the patient with hormone refractory prostate cancerP S Esper, K J Pienta
Annals of Internal Medicine|May 15, 1993
Risk factors for prostate cancerK J Pienta, P S Esper
American Journal of Clinical Oncology|October 1, 1996
A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostateK J Pienta, B G Redman, P S Esper, et al.
American Journal of Clinical Oncology|February 1, 1997
Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostateK J Pienta, P S Esper, F Zwas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostateK J Pienta, B Redman, M Hussain, et al.
Urology|September 25, 1997
A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancerK J Pienta, B G Redman, R Bandekar, et al.
Pageof 1